Text Size

Omidenepag Isopropyl Versus Timolol in Patients With Glaucoma or Ocular Hypertension: Two Randomized Phase 3 Trials (SPECTRUM 4 and 3)

Bacharach J., Brubaker J.W., Evans D.G., LU F., Odani-Kawabata N., Yamabe T., Wirta D.L.


  • 2024
  • American Journal of Ophthalmology
View publication
  • Therapeutic Area

    Glaucoma

  • Categories

    Clinical development

  • Affiliations

    From the North Bay Eye Associates (J.B.), Petaluma, CA, United States; Sacramento Eye Consultants (J.W.B.), Sacramento, CA, United States; Total Eye Care, P.A.(D.G.E.), Memphis, TN, United States; Santen, Inc.(F.L., T.Y.), Emeryville, CA, United States; Santen Pharmaceutical Co., Ltd (N.O.-K., T.Y.), Osaka, Japan; Eye Research Foundation (D.L.W.), Newport Beach, CA, United States

Related Publications

Felodipine re-positioned as a neuroprotectant via improved optic nerve head blood circulation in retinal ischemic rabbits and ocular hypertensive rats

Taniguchi T, Akaishi T, Hata T, Yamashita R, Esaki Y, Morofuji R, Okabe K, Fuwa M, Yamamoto Y, Guo L, Choi S, Luong V, Ota T, Sharif NA, Cordeiro MF, Kageyama M.


A Study of 24-h Efficacy and Safety of Sepetaprost vs. Latanoprost in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension

Konstas A.G.; Garhöfer G.; Lübke Y.; Voykov B.; Ropo A.


Valproic Acid Application to Modify Post Surgical Fibrosis in a Model of Minimally Invasive Bleb Surgery

Lo P.F.; Gunawan M.; Yap Z.L.; Leong C.; Kwek F.; Varadarajan J.; Wang X.; Kageyama M.; Wong T.T.


Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022